Trends in Biochemical Sciences
ReviewCyclosporin A, FK506 and rapamycin: more than just immunosuppression
References (35)
Cell
(1991)Cell
(1993)Gene
(1991)Gene
(1989)Gene
(1992)- et al.
Trends Cell Biol.
(1992) Cell
(1992)Cell
(1992)Cell
(1991)- et al.
Trends Cell Biol.
(1992)
Curr. Opin. Immunol.
Annu. Rev. Immunol.
Science
New Biologist
Nature
Immunol. Today
Nature
Cited by (265)
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
2024, European Journal of Medicinal ChemistryA novel formulation of cyclosporine A/phosphatidylserine-containing liposome using remote loading method: Potential product for immunosuppressive effects
2022, Journal of Drug Delivery Science and TechnologyCitation Excerpt :Among these substances, Cyclosporine A (CsA) is widely used to prevent transplanted organ rejection and auto-immune diseases [2]. As a potent immunosuppressive drug, CsA reduces the graft organ rejection and improves graft survival after transplantation through suppression of T-cell activation or proliferation and also inhibition of IL-2 receptor pathway [3]. In addition to inhibiting calcineurin phosphatase activity, CsA also inhibits nuclear translocation and subsequent transcription factor activation via the interactions formed with cyclophilin.
Roles of TOR signaling in nutrient deprivation and abiotic stress
2022, Journal of Plant PhysiologyBiophysical and biochemical characterization of a thermostable archaeal cyclophilin from Methanobrevibacter ruminantium
2019, International Journal of Biological MacromoleculesTwo low complexity ultra-high throughput methods to identify diverse chemically bioactive molecules using Saccharomyces cerevisiae
2017, Microbiological ResearchCitation Excerpt :This shows that the compounds scored from the yeast HTS are similarly diverse as those from other sources, and hit >25% of the targets encoded by the yeast genome (Fig. 5d). Examples of yeast bioactives scoring known targets include squalestatin hitting Erg9, nocodazole targeting the microtubule machinery (Saunders et al., 1997), aureobasidin inhibiting the inositol phosphorylceramide (Zhong et al., 2000), rapamycin (Adami et al., 2007; Kunz and Hall, 1993), reveromycin (Miyamoto et al., 2002), and concanamycin (Hoepfner et al., 2014) (Fig. 6a–f). In addition, compounds originating from the HTS described here were shown to target the translation initiation machinery – rocaglamide (Sadlish et al., 2013), and the sterol-4-alpha-carboxylate-3-dehydrogenase – FR171456 (Helliwell et al., 2015) (Fig. 6g and h).